Inactive Instrument

Highlights Spark Therapeutics Inc Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
-	-

2023	Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	CI
2023	Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	23-10-14	CI
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	23-01-27	CI
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	22-12-12	CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	21-12-16	CI
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII Expression that Significantly Reduced Bleeding in Hemophilia A Patients	21-11-17	CI
CombiGene in Billion-Dollar Deal with Spark Therapeutics	21-10-12	CI
NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease	21-09-07	CI
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date	21-07-21	CI
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform	21-04-13	CI
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress	21-02-05	CI
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease	21-02-01	CI
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress	20-07-12	CI
Spark Therapeutics, Inc. Demonstrates Role of Ides in Enabling of Gene Therapy in the Presence of Neutralizing Anti-Aav Antibodies Published in Nature Medicine	20-06-01	CI
Roche Holding AG completed the acquisition of Spark Therapeutics, Inc..	19-12-15	CI
Spark Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Spark Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-08	CI
Spark Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-10	CI
Roche Holding AG entered into a definitive merger agreement to acquire Spark Therapeutics, Inc. for $4.5 billion.	19-02-24	CI
Spark Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-02-19	CI
Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™	19-01-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Spark Therapeutics Inc Nasdaq

Equities

Highlights

Filters